Please provide your email address to receive an email when new articles are posted on . MADRID — Hossein Borghaei, DO, MS, discussed results from the ALINA study on ALK-positive non-small cell lung ...
What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...
Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), investigators compared outcomes vs chemotherapy. ALK-positive disease accounts ...
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer. Ensacove (ensartinib) has been approved by the Food and Drug ...
Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract ...
Rearrangements of ALK genes are extremely rare events in PDAC accounting for only 0.16% of the case. ALK rearrangements are mutually exclusive with mutations of KRAS and are present exclusively in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results